{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:37:57Z","timestamp":1781649477900,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T00:00:00Z","timestamp":1523232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00228-018-2456-y","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T11:42:13Z","timestamp":1523274133000},"page":"971-978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden"],"prefix":"10.1007","volume":"74","author":[{"given":"P.","family":"Frisk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Aggefors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Feltelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Loov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wettermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Weiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,9]]},"reference":[{"issue":"11","key":"2456_CR1","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/jmv.24554","volume":"88","author":"LS Wang","year":"2016","unstructured":"Wang LS, D\u2019Souza LS, Jacobson IM (2016) Hepatitis C\u2014a clinical review. J Med Virol 88(11):1844\u20131855. \n                    https:\/\/doi.org\/10.1002\/jmv.24554","journal-title":"J Med Virol"},{"issue":"4","key":"2456_CR2","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57(4):1333\u20131342","journal-title":"Hepatology"},{"issue":"2","key":"2456_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.7326\/0003-4819-158-2-201301150-00576","volume":"158","author":"R Chou","year":"2013","unstructured":"Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R (2013) Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 158(2):114\u2013123","journal-title":"Ann Intern Med"},{"issue":"20","key":"2456_CR4","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMra1213651","volume":"368","author":"TJ Liang","year":"2013","unstructured":"Liang TJ, Ghany MG (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 368(20):1907\u20131917. \n                    https:\/\/doi.org\/10.1056\/NEjMra1213651","journal-title":"N Engl J Med"},{"issue":"6","key":"2456_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jama.2014.8897","volume":"312","author":"T Brennan","year":"2014","unstructured":"Brennan T, Shrank W (2014) New expensive treatments for hepatitis C infection. JAMA 312(6):593\u2013594","journal-title":"JAMA"},{"issue":"5","key":"2456_CR6","first-page":"1","volume":"14","author":"A Anell","year":"2012","unstructured":"Anell A, Glenng\u00e5rd AH, Merkur S (2012) Sweden health system review. Health Syst Transit 14(5):1\u2013159","journal-title":"Health Syst Transit"},{"key":"2456_CR7","unstructured":"TLV. Patient co-payment scheme for prescription drugs. [Internet]. Accessed 5 October 2017. \n                    http:\/\/www.tlv.se\/In-English\/medicines-new\/the-swedish-high-cost-threshold\/how-it-works\/"},{"key":"2456_CR8","unstructured":"SFS 2004:168 Swedish government Communicable disease law [Internet]. Accessed 5 October 2017. http:\/\/www.riksdagen.se\/sv\/dokument-lagar\/dokument\/svensk-forfattningssamling\/smittskyddslag-2004168_sfs-2004-168"},{"key":"2456_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/00365521.2016.1228119","volume":"52","author":"K B\u00fcsch","year":"2016","unstructured":"B\u00fcsch K, Waldenstr\u00f6m J, Lagging M, Aleman S, Weiland O, K\u00f6vamees J, Duberg AS, S\u00f6derholm J (2016) Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scand J Gastroenterol 52:61\u201368. \n                    https:\/\/doi.org\/10.1080\/00365521.2016.1228119","journal-title":"Scand J Gastroenterol"},{"key":"2456_CR10","unstructured":"L\u00e4kemedelsbehandling av hepatit C-virusinfektion hos vuxna och barn - kunskapsunderlag. Information fr\u00e5n L\u00e4kemedelsverket. 2014."},{"key":"2456_CR11","volume-title":"Ordnat inf\u00f6rande i samverkan: slutrapport fr\u00e5n nationella l\u00e4kemedelsstrategin, delprojekt 6.1","author":"Sveriges kommuner och landsting","year":"2014","unstructured":"Sveriges kommuner och landsting (2014) Ordnat inf\u00f6rande i samverkan: slutrapport fr\u00e5n nationella l\u00e4kemedelsstrategin, delprojekt 6.1. Sveriges Kommuner och Landsting, Stockholm"},{"key":"2456_CR12","unstructured":"New drug therapies for hepatitis C A national introduction- and monitoring protocol (version 6.0) [Internet]. Accessed 18 August 2016 \n                    http:\/\/www.janusinfo.se\/Documents\/Nationellt_inforande_av_nya_lakemedel\/Inforande-och-uppfoljningsprotokoll-for-lakemedel-mot-hepatit-C-Version-6.pdf"},{"issue":"7","key":"2456_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, MichaelFored C, Leimanis A, Otterblad Olausson P et al (2007) The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726\u2013735","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2456_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim J-L, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450. \n                    https:\/\/doi.org\/10.1186\/1471-2458-11-450.","journal-title":"BMC Public Health"},{"issue":"1","key":"2456_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/joim.12303","volume":"277","author":"L Emilsson","year":"2015","unstructured":"Emilsson L, Lindahl B, K\u00f6ster M, Lambe M, Ludvigsson JF (2015) Review of 103 Swedish healthcare quality registries. J Intern Med 277(1):94\u2013136","journal-title":"J Intern Med"},{"issue":"11","key":"2456_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A (2009) The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24(11):659\u2013667","journal-title":"Eur J Epidemiol"},{"key":"2456_CR17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40261-017-0565-5","volume":"37","author":"H Ahmed","year":"2017","unstructured":"Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA, Abdel-Daim MM (2017) Safety and efficacy of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: a systematic review and meta-analysis. Clin Drug Investig 37:1009\u20131023. \n                    https:\/\/doi.org\/10.1007\/s40261-017-0565-5\n                    \n                  . [Epub ahead of print]","journal-title":"Clin Drug Investig"},{"issue":"Suppl 1","key":"2456_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/liv.13293","volume":"37","author":"R Flisiak","year":"2017","unstructured":"Flisiak R, Pogorzelska J, Flisiak-Jackiewicz M (2017) Hepatitis C: efficacy and safety in real life. Liver Int 37(Suppl 1):26\u201332. \n                    https:\/\/doi.org\/10.1111\/liv.13293","journal-title":"Liver Int"},{"issue":"11","key":"2456_CR19","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","volume":"65","author":"TM Welzel","year":"2016","unstructured":"Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S (2016) Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 65(11):1861\u20131870","journal-title":"Gut"},{"issue":"5","key":"2456_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/00365521.2017.1283439","volume":"52","author":"C Maria","year":"2017","unstructured":"Maria C, Michael S, Susanne C, Catarina S, Ola W (2017) INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse\u2014a Swedish real life experience. Scand J Gastroenterol 52(5):585\u2013588","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"2456_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179764","volume":"12","author":"O Dalgard","year":"2017","unstructured":"Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L, F\u00e4rkkil\u00e2 M, Balslev U, Belard E, \u00d8vrehus A, Skalsh\u00f8i Kj\u00e6r M, Krarup H, Thorup R\u00f8ge B, Hallager S, Madsen LG, Lund Laursen A, Lagging M, Weis N (2017) Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections\u2014a Scandinavian real-life study. PLoS One 12(7):e0179764","journal-title":"PLoS One"},{"issue":"1","key":"2456_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12879-016-2106-x","volume":"17","author":"J Young","year":"2017","unstructured":"Young J, Weis N, Hofer H, Irving W, Weiland O, Giostra E, Pascasio JM, Castells L, Prieto M, Postema R, Lefevre C, Evans D, Bucher HC, Calleja JL (2017) The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. BMC Infect Dis 17(1):45. \n                    https:\/\/doi.org\/10.1186\/s12879-016-2106-x","journal-title":"BMC Infect Dis"},{"key":"2456_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/jmv.24903","volume":"90","author":"MH Wehmeyer","year":"2017","unstructured":"Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze zur Wiesch J (2017) Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol 90:304\u2013312. \n                    https:\/\/doi.org\/10.1002\/jmv.24903\n                    \n                  . [Epub ahead of print]","journal-title":"J Med Virol"},{"issue":"4","key":"2456_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1365-2710.2008.00925.x","volume":"33","author":"D Chauhan","year":"2008","unstructured":"Chauhan D, Mason A (2008) Factors affecting the uptake of new medicines in secondary care a literature review. J Clin Pharm Ther 33(4):339\u2013348","journal-title":"J Clin Pharm Ther"},{"key":"2456_CR25","unstructured":"Ordning i leden? Utv\u00e4rdering av ordnat inf\u00f6rande av nya l\u00e4kemedel. Rapport 2017:5 [Internet]. Myndigheten f\u00f6r v\u00e5rd- och omsorgsanalys. Accessed 15 August 2017. \n                    www.vardanalys.se\/Rapporter\/2017\/Ordning-i-leden\/"},{"key":"2456_CR26","unstructured":"Aggregated statistics from the Swedish eHealth Agency [Internet]. \n                    www.ehalsomyndigheten.se"},{"issue":"4","key":"2456_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","volume":"47","author":"ZD Goodman","year":"2007","unstructured":"Goodman ZD (2007) Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 47(4):598\u2013607","journal-title":"J Hepatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2456-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2456-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2456-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T01:37:13Z","timestamp":1554773833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2456-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,9]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2456"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2456-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,9]]},"assertion":[{"value":"22 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The views in this paper are those of the authors and not necessarily representative of the governmental agencies at which they are employed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}}]}}